Ignyta Reports Granting of Inducement Awards
August 18 2017 - 4:00PM
Business Wire
Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company
focused on precision medicine in oncology, announced today that it
has issued an inducement award to one new non-executive
employee.
The award was made on August 17, 2017, under Ignyta’s 2017
Employment Inducement Equity Incentive Award Plan, which was
adopted August 17, 2017, and provides for the granting of equity
awards to new employees of Ignyta. The inducement award was not
individually negotiated and consists of an option to purchase an
aggregate of 70,000 shares of Ignyta common stock and has a
ten-year term. The exercise price of the option was $9.65, which
was the per-share closing price of Ignyta’s common stock on the
Nasdaq Capital Market on August 17, 2017. The option vests over a
four-year period, with 25% vesting on the first anniversary of the
date of hire and the remainder vesting in equal monthly
installments over the three years thereafter. The award was
approved by the independent compensation committee of Ignyta’s
board of directors and was granted as an inducement material to the
new employee entering into employment with Ignyta in accordance
with Nasdaq Marketplace Rule 5635(c)(4).
About Ignyta, Inc.
Blazing a New Future for Patients with
Cancer™
At Ignyta, we work tirelessly on behalf of patients with cancer
to offer potentially life-saving, precisely targeted therapeutics
(Rx) guided by companion diagnostic (Dx) tests. Our integrated
Rx/Dx strategy allows us to enter uncharted territory, illuminating
the molecular drivers of cancer and quickly advancing treatments to
address them. This approach embraces even those patients with the
rarest cancers, who have the highest unmet need and who may
otherwise not have access to effective treatment options. With our
pipeline of potentially first-in-class or best-in-class precision
medicines, we are pursuing the ultimate goal of not just shrinking
tumors, but eradicating cancer relapse and recurrence in precisely
defined patient populations.
For more information, please visit: www.ignyta.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170818005468/en/
Ignyta, Inc.Jacob Chacko, M.D.CFO858-255-5959jc@ignyta.com
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Apr 2023 to Apr 2024